Cymabay Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cymabay Therapeutics Inc (CBAY) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cymabay Therapeutics Inc vs Its Competitors
- Profitability: Its -73,512.3% net margin compares with 28.4% for the peer group.
- Peer revenue share: Cymabay Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CBAY Sales vs. its Competitors, Q4 2023
With a net margin of -73,512.28 %, Cymabay Therapeutics Inc reported lower profitability than its competitors (28.39 %).
Cymabay Therapeutics Inc generated 0.00 % of the combined sales of its peer group.
API endpoints for this dataset
Cymabay Therapeutics Inc vs. its Competitors, Q4 2023
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Cymabay Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cymabay Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cymabay Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (52) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cymabay Therapeutics Inc's competitor groups requires a Commercial License.
Cymabay Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cymabay Therapeutics Inc | - | - | - | Yes |
| Competitors combined (20) | ||||
| High-Confidence Competitors (61) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CBAY Stock Performance relative to its Competitors
CBAY Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Akero Therapeutics Inc | 282.9% | Outperformed |
| 2 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 3 | Diamedica Therapeutics Inc | 282.9% | Outperformed |
| 4 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Mirum Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cymabay Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cymabay Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cymabay Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Cymabay Therapeutics Inc |
3,449.52 | - |
 Vertex Pharmaceuticals Inc |
137,450.72 | 12,951.60 |
 Regeneron Pharmaceuticals Inc |
100,897.63 | 16,896.20 |
 Horizon Therapeutics Public Limited Company |
27,190.33 | 3,643.45 |
 Madrigal Pharmaceuticals Inc |
12,955.53 | 1,427.94 |
 Mirum Pharmaceuticals Inc |
6,208.02 | 670.78 |
| SUBTOTAL | 302,460.39 | 36,353.99 |
Sign in to see all competitors of Cymabay Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cymabay Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cymabay Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Cymabay Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Autolus Therapeutics Plc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Tevogen Bio Holdings Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Aptevo Therapeutics Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Agenus Inc | Company report | 85% |
| Alfasigma S.p.A. | Company report | 85% |
| ENTO | Company report | 85% |
| Eiger Biopharmaceuticals Inc | Company report | 85% |
| Intercept Pharmaceuticals | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Assembly Biosciences Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| PHGEU | Company report | 85% |
| Genfit S a | Company report | 85% |
| Jasper Therapeutics Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Biomx Inc | Company report | 85% |
| GLTO | Company report | 85% |
| Damora Therapeutics Inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| RENB | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Cocrystal Pharma Inc | Company report | 85% |
| Senti Biosciences Holdings Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Vir Biotechnology Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Sanofi | Company report | 85% |
| Atea Pharmaceuticals Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Chimerix Inc | Company report | 85% |
| Sorrento Therapeutics Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Viking Therapeutics Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Iteos Therapeutics Inc | Company report | 85% |
| Atara Biotherapeutics Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Aligos Therapeutics Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Argenx Se | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Cymabay Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Cymabay Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Jaguar Health Inc | Human Health Segment 95.92 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cymabay Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cymabay Therapeutics Inc | 3,450 | - | -1,549,559 |
| Vertex Pharmaceuticals Inc | 137,451 | 31,979,259 | 9,817,037 |
| Regeneron Pharmaceuticals Inc | 100,898 | 1,096,444 | 312,615 |
| Horizon Therapeutics Public Limited Company | 27,190 | 2,802,652 | 336,925 |
| Madrigal Pharmaceuticals Inc | 12,956 | 1,560,590 | -169,905 |
| Mirum Pharmaceuticals Inc | 6,208 | 1,803,167 | -2,429,780 |
| PEERS TOTAL | 299,011 | 1,863,734 | 352,155 |
Sign in to see all peers for Cymabay Therapeutics Inc .
Cymabay Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Horizon Therapeutics Public Limited Company | United States 97.76 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cymabay Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.3x | - |
| EV / EBITDA | - | 15.1x | - |
| P/B | 9.1x | 4.2x | +4.9x |
| Return on Equity | -50.72 % | industry aggregate | -63.95 % |
| Return on Invested Capital | -19.67 % | -9.73 % (avg) | -9.94 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cymabay Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -57.30 % | -77.85 % | -22.31 % | -25.58 % | - | -35.50 % | -40.89 % | -19.67 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cymabay Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 64.0 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (55.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-24.0% annualized).
Methodology: see Methodology: SWOT Analysis.
Cymabay Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cymabay Therapeutics Inc | 4.75 | 10.90 | - |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Horizon Therapeutics Public Limited Company | 2.57 | 4.04 | 0.50 |
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
| Mirum Pharmaceuticals Inc | 1.21 | 2.38 | 4.27 |
Sign in to see all peers for Cymabay Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cymabay Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cymabay Therapeutics Inc | Q4 2023 | - | - |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Horizon Therapeutics Public Limited Company | Q2 2023 | +7.7 % | +108.4 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| Mirum Pharmaceuticals Inc | Q3 2026 | +39.6 % | - |
| PEERS TOTAL | +23.3 % | -4.2 % |
Sign in to see all peers for Cymabay Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cymabay Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cymabay Therapeutics Inc | Q4 2023 | - | +1,284.6 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Horizon Therapeutics Public Limited Company | Q2 2023 | -4.9 % | +81.9 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
| Mirum Pharmaceuticals Inc | Q3 2026 | - | +597.9 % |
Sign in to see all peers for Cymabay Therapeutics Inc .
Cymabay Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cymabay Therapeutics Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Horizon Therapeutics Public Limited Company | 4.81% | 5.71% | 8.54% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Mirum Pharmaceuticals Inc | - | - | - |
Sign in to see all peers for Cymabay Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cymabay Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cymabay Therapeutics Inc | - | - |
| Vertex Pharmaceuticals Inc | 34.73 | 10.61 |
| Regeneron Pharmaceuticals Inc | 21.13 | 5.97 |
| Horizon Therapeutics Public Limited Company | 62.49 | 7.46 |
| Madrigal Pharmaceuticals Inc | - | 9.07 |
| Mirum Pharmaceuticals Inc | - | 9.25 |
| PEERS AVERAGE | 44.72 | 8.32 |
Sign in to see all peers for Cymabay Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.